European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
All content for European Pharmaceutical Review podcast is the property of European Pharmaceutical Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
Ocugen is utilising the modifier gene therapy technology approach to treat retinal diseases. The therapy can be used to treat both inherited disorders, such as retinitis pigmentosa (RP), Leber congenital amaurosis, and Stargardt disease, but also multifactorial diseases like dry age-related macular degeneration and angiographic atrophy.
The company’s lead candidate in modifier gene therapy, OCU400, is in Phase III trials for treatment of RP and Phase I/II for treatment of Leber congenital amaurosis.
European Pharmaceutical Review podcast
European Pharmaceutical Review’s podcasts interview some of the leading experts and scientists about the latest developments in the pharmaceutical and life science sectors.
